The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Cyclooxygenase Inhibition and Cardiovascular Risk
Abstract
Over the past several months clinicians have been con-fronted at an escalating rate with reports describing the risks of COX-2 inhibitors (coxibs). Information on this class of drugs appears not only in traditional medical journals and textbooks, but also on the Web sites of regulatory agencies, professional societies, and pharmaceutical manufacturers.1–9 An unusual, but noteworthy, aspect of the state of affairs is the high rate of reporting new findings and opinions (at times voiced in a strident tone) in the lay press.10–13 Understand-ably, patients are concerned about the potential risks associ-ated with their antiinflammatory medications, and now, either spontaneously or in response to a public health warning, call their healthcare professional with questions or arrive for an office visit armed with publicly accessed information they wish to discuss. Owing to the widespread use of antiinflammatory drugs
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Leukotrienes and Lipoxins: Structures, Biosynthesis, and Biological Effects
Samuelsson, B., Dahlén, S.-E., Lindgren, J. Å., Rouzer, C. A., & Serhan, C. N. (1987) · Science · doi:10.1126/science.2820055 · Cited by 2,233
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Basic and Clinical Pharmacology
Katzung, B. G. (1982) · Andalas University Repository (Andalas University) · Cited by 1,914
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003199 · Cited by 1,394
McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
Hawkey, C. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12154-2 · Cited by 1,173
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke
Helgadottir, A., Manolescu, A., Thorleifsson, G., Gretarsdottir, S., Jonsdottir, H., Thorsteinsdottir, U., Samani, N. J., Gudmundsson, G., Grant, S. F. A., Thorgeirsson, G., et al. (2004) · Nature Genetics · doi:10.1038/ng1311 · Cited by 927
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Huang, J.-Q., Sridhar, S., & Hunt, R. H. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07273-2 · Cited by 901
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Endothelial Dysfunction, Hemodynamic Forces, and Atherogenesisa
GIMBRONE, M. A., TOPPER, J. N., NAGEL, T., ANDERSON, K. R., & GARCIA‐CARDEÑA, G. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06318.x · Cited by 836
Arachidonate 5-Lipoxygenase Promoter Genotype, Dietary Arachidonic Acid, and Atherosclerosis
Dwyer, J. H., Allayee, H., Dwyer, K. M., Fan, J., Wu, H., Mar, R., Lusis, A. J., & Mehrabian, M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa025079 · Cited by 619
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
Warner, T. D., & Mitchell, J. A. (2004) · The FASEB Journal · doi:10.1096/fj.03-0645rev · Cited by 614
Hippisley-Cox, J., & Coupland, C. (2005) · BMJ · doi:10.1136/bmj.330.7504.1366 · Cited by 561
Solomon, D. H., Schneeweiss, S., Glynn, R. J., Kiyota, Y., Levin, R., Mogun, H., & Avorn, J. (2004) · Circulation · doi:10.1161/01.cir.0000127578.21885.3e · Cited by 509
Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet Activation
FitzGerald, G. A., Smith, B., Pedersen, A. K., & Brash, A. R. (1984) · New England Journal of Medicine · doi:10.1056/nejm198404263101701 · Cited by 497
Farkouh, M. E., Kirshner, H., Harrington, R. A., Ruland, S., Verheugt, F. W., Schnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16894-3 · Cited by 490
Recent considerations in nonsteroidal anti-inflammatory drug gastropathy
Singh, G. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00072-2 · Cited by 457
Weksler, B. B., Pett, S. B., Alonso, D., Richter, R. C., Stelzer, P., Subramanian, V., Tack-Goldman, K., & Gay, W. A. (1983) · New England Journal of Medicine · doi:10.1056/nejm198304073081402 · Cited by 448
COX-2-Derived Prostacyclin Confers Atheroprotection on Female Mice
Egan, K. M., Lawson, J. A., Fries, S., Koller, B., Rader, D. J., Smyth, E. M., & FitzGerald, G. A. (2004) · Science · doi:10.1126/science.1103333 · Cited by 431
Mehrabian, M., Allayee, H., Wong, J., Shih, W., Wang, X.-P., Shaposhnik, Z., Funk, C. D., & Lusis, A. J. (2002) · Circulation Research · doi:10.1161/01.res.0000028008.99774.7f · Cited by 422
Serhan, C. N., Jain, A., Marleau, S., Clish, C., Kantarci, A., Behbehani, B., Colgan, S. P., Stahl, G. L., Merched, A., Petasis, N. A., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6856 · Cited by 404
Augmented Expression of Cyclooxygenase-2 in Human Atherosclerotic Lesions
Schönbeck, U., Sukhova, G. K., Graber, P., Coulter, S., & Libby, P. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65230-3 · Cited by 379
Cyclooxygenase-1 and -2–Dependent Prostacyclin Formation in Patients With Atherosclerosis
Belton, O., Byrne, D., Kearney, D., Leahy, A., & Fitzgerald, D. J. (2000) · Circulation · doi:10.1161/01.cir.102.8.840 · Cited by 377
Kobayashi, T., Tahara, Y., Matsumoto, M., Iguchi, M., Sano, H., Murayama, T., Arai, H., Oida, H., Yurugi-Kobayashi, T., Yamashita, J. K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421446 · Cited by 373
Cipollone, F., Prontera, C., Pini, B., Marini, M., Fazia, M., De Cesare, D., Iezzi, A., Ucchino, S., Boccoli, G., Saba, V., et al. (2001) · Circulation · doi:10.1161/hc3401.093152 · Cited by 351
Swan, S. K., Rudy, D. W., Lasseter, K. C., Ryan, C. F., Buechel, K. L., Lambrecht, L. J., Pinto, M. B., Dilzer, S. C., Obrda, O., Sundblad, K. J., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-1-200007040-00002 · Cited by 339
Prostaglandin E2 Suppresses Chemokine Production in Human Macrophages through the EP4 Receptor
Takayama, K., Garcı́a-Cardeña, G., Sukhova, G. K., Comander, J., Gimbrone, M. A., & Libby, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204810200 · Cited by 337
Meta-analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure
(2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.5.ioi50013 · Cited by 329
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
ROSSAT, J., MAILLARD, M., NUSSBERGER, J., BRUNNER, H., & BURNIER, M. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70056-1 · Cited by 318
Carlson, L. A., & Rössner, S. (1978) · Atherosclerosis · doi:10.1016/0021-9150(78)90051-5 · Cited by 314
Johnsen, S. P. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.9.978 · Cited by 288
Cyclooxygenase-2 Promotes Early Atherosclerotic Lesion Formation in LDL Receptor–Deficient Mice
Burleigh, M. E., Babaev, V. R., Oates, J. A., Harris, R. C., Gautam, S., Riendeau, D., Marnett, L. J., Morrow, J. D., Fazio, S., & Linton, M. F. (2002) · Circulation · doi:10.1161/01.cir.0000014927.74465.7f · Cited by 279
Chiang, N., Bermudez, E. A., Ridker, P. M., Hurwitz, S., & Serhan, C. N. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405445101 · Cited by 266
Bolli, R. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00414-5 · Cited by 258
Lévesque, L. E., Brophy, J. M., & Zhang, B. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00113 · Cited by 249
Ofman, J. J., MacLean, C. H., Straus, W. L., Morton, S. C., Berger, M. L., Röth, E., & Shekelle, P. (2002) · PubMed · Cited by 239
Cayatte, A. J., Du, Y., Oliver-Krasinski, J., Lavielle, G., Verbeuren, T. J., & Cohen, R. A. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.7.1724 · Cited by 237
(2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.2.161 · Cited by 233
Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction
Kimmel, S. E., Berlin, J. A., Reilly, M., Jaskowiak, J., Kishel, L., Chittams, J., & Strom, B. L. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-3-200502010-00005 · Cited by 222
C-Reactive Protein Decreases Prostacyclin Release From Human Aortic Endothelial Cells
Venugopal, S. K., Devaraj, S., & Jialal, I. (2003) · Circulation · doi:10.1161/01.cir.0000094736.10595.a1 · Cited by 184
Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs
Moreno‐Sánchez, R., Bravo, C., Vásquez-Trincado, C., Ayala, G., Silveira, L. H., & Martínez‐Lavín, M. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00330-x · Cited by 168
Short- and Long-Term COX-2 Inhibition Reverses Endothelial Dysfunction in Patients With Hypertension
Widlansky, M. E., Price, D. T., Gokce, N., Eberhardt, R. T., Duffy, S. J., Holbrook, M., Maxwell, C., Palmisano, J., Keaney, J. F., Morrow, J. D., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000084603.93510.28 · Cited by 158
12/15-Lipoxygenase, Oxidative Modification of LDL and Atherogenesis
Cyrus, C. (2001) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(01)00096-2 · Cited by 139
Schmidt, P., Youhnovski, N., Daiber, A., Balan, A., Arsic, M., Bachschmid, M. M., Przybylski, M., & Ullrich, V. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208080200 · Cited by 138
Parecoxib, Valdecoxib, and Cardiovascular Risk
Furberg, C. D., Psaty, B. M., & FitzGerald, G. A. (2005) · Circulation · doi:10.1161/01.cir.0000155081.76164.17 · Cited by 128
The Research on Adverse Drug Events and Reports (RADAR) Project
Bennett, C. L. (2005) · JAMA · doi:10.1001/jama.293.17.2131 · Cited by 123
Ma, H., Hara, A., Xiao, C. Y., Okada, Y., Takahata, O., Nakaya, K., Sugimoto, Y., Ichikawa, A., Narumiya, S., & Ushikubi, F. (2001) · Circulation · doi:10.1161/hc3601.094003 · Cited by 110
Penglis, P. S., Cleland, L. G., Demasi, M., Caughey, G. E., & James, M. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.3.1605 · Cited by 108
The lessons of Vioxx—drug safety and sales
Waxman, H. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmp058136 · Cited by 99
Practical aspects of decision making in clinical trials: The coronary drug project as a case study
The Coronary Drug Project Research Group (1981) · Controlled Clinical Trials · doi:10.1016/0197-2456(81)90041-6 · Cited by 98
Niwano, K., Arai, M., Tomaru, K., Uchiyama, T., Ohyama, Y., & Kurabayashi, M. (2003) · Circulation Research · doi:10.1161/01.res.0000091336.55487.f7 · Cited by 94
Stamler, J. S., Vaughan, D. E., & Loscalzo, J. (1989) · Circulation Research · doi:10.1161/01.res.65.3.796 · Cited by 92
Self-citationBachschmid, M. M., Thurau, S., Zou, M., & Ullrich, V. (2003) · The FASEB Journal · doi:10.1096/fj.02-0530fje · Cited by 90
Muzaffar, S., Shukla, N., Lobo, C., Angelini, G. D., & Jeremy, J. Y. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705626 · Cited by 88
Singh, G., Miller, J. D., Huse, D. M., et al. (2003) · PubMed · Cited by 85
The Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
BENNETT, J. S., Daugherty, A., Herrington, D. M., Greenland, P., Roberts, H. R., & Taubert, K. A. (2005) · Circulation · doi:10.1161/01.cir.0000160005.90598.41 · Cited by 84
Rott, D., Zhu, J., Burnett, M. S., Zhou, Y., Zalles-Ganley, A., Ogunmakinwa, J., & Epstein, S. E. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00304-8 · Cited by 80
Regulation of Cyclooxygenase-2 Expression by Nitric Oxide in Cells
Pérez‐Sala, D., & Lamas, S. (2001) · Antioxidants and Redox Signaling · doi:10.1089/152308601300185197 · Cited by 77
Coffey, M., Phare, S. M., & Peters-Golden, M. L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.7.3592 · Cited by 68
Bulut, D., Liaghat, S., Hanefeld, C., Koll, R., Miebach, T., & gge, A. M. U. (2003) · Journal of Hypertension · doi:10.1097/00004872-200309000-00015 · Cited by 65
Effects of low‐dose aspirin on endothelial function in hypertensive patients
Monobe, H., Yamanari, H., Nakamura, K., & Ohe, T. (2001) · Clinical Cardiology · doi:10.1002/clc.4960241104 · Cited by 64
Transcellular metabolism of eicosanoids.
Aj, M. (1986) · PubMed · Cited by 51
No Effect of Cyclooxygenase Inhibition on Plaque Size in Atherosclerosis-prone Mice
Olesen, M., Kwong, E. C., Meztli, A., Kontny, F. P., Seljeflot, I., Arnesen, H., Lyngdorf, L. G., & Falk, E. (2002) · Scandinavian Cardiovascular Journal · doi:10.1080/140174302762659094 · Cited by 47
5-Lipoxygenase is involved in the angiotensin II-induced NAD(P)H-oxidase activation
Luchtefeld, M., Drexler, H., & Schieffer, B. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01456-6 · Cited by 47
Coffey, M., Phare, S. M., & Peters-Golden, M. L. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(02)00286-x · Cited by 46
Wade, M. L., & Fitzpatrick, F. A. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.0348 · Cited by 41
SStamler, J., EVaughan, D., & JLoscalzo (1989) · Circulation Research · Cited by 41
Interactions of nitric oxide-derived reactive nitrogen species with peroxidases and lipoxygenases
Coffey, M. J., Coles, B., & O’Donnell, V. B. (2001) · Free Radical Research · doi:10.1080/10715760100301471 · Cited by 30
The US Food and Drug Administration Cardiorenal Advisory Panel and the Drug Approval Process
Roden, D. M., & Temple, R. (2005) · Circulation · doi:10.1161/01.cir.0000161370.77463.0f · Cited by 20
Role of nitric oxide in the metabolism of arachidonic acid in the rat anterior pituitary gland
Velardez, M. O., Ogando, D. G., Franchi, A. M., & Duvilanski, B. H. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(00)00399-3 · Cited by 11
Cited by
Writing Committee Members, Bhatt, D. L., Scheiman, J., Abraham, N. S., Antman, E. M., Chan, F. K. L., Furberg, C. D., Johnson, D. A., Mahaffey, K. W., & Quigley, E. M. (2008) · Circulation · doi:10.1161/circulationaha.108.191087 · Cited by 843
Self-citationCamenzind, E., Steg, P. G., & Wijns, W. (2007) · Circulation · doi:10.1161/circulationaha.106.666800 · Cited by 818
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804
Self-citationJelic, S., Padeletti, M., Kawut, S. M., Higgins, C., Canfield, S. M., Onat, D., Colombo, P. C., Basner, R. C., Factor, P., & LeJemtel, T. H. (2008) · Circulation · doi:10.1161/circulationaha.107.741512 · Cited by 618
Using Recovery Modalities between Training Sessions in Elite Athletes: Does it Help?
Barnett, A. (2006) · Sports Medicine · doi:10.2165/00007256-200636090-00005 · Cited by 593
Metadata
- Authors
- Antman, E. M., DeMets, D., & Loscalzo, J.
- Venue
- Circulation
- Published
- 2005-08-02
- Volume
- 112
- Issue
- 5
- Pages
- 759-770
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2014184499
- Cited by
- 282
- References
- 75
- FWCI
- 17.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.